H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating

Core Insights - uniQure N.V. has been identified as a hot growth stock, with a price target increase from $70 to $110 by H.C. Wainwright, maintaining a Buy rating [1][2] - The bullish outlook is driven by promising results from AMT-130 trials for Huntington's disease, showing a significant slowdown in disease progression and improvements in biomarkers [2] Company Overview - uniQure N.V. specializes in gene therapy, focusing on developing one-time gene therapies aimed at potentially curing genetic and serious diseases [3]